Skip to main content
Mobile  •  Daphne  •  Click to View Office Locations
A A A
(Adjust font size)

Keratoconus

 

What Is Keratoconus?

Keratoconus, often referred to as “KC,” is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge and optical irregularity of the cornea. This causes “static” in your vision and can result in significant visual impairment.

 Symptoms

Keratoconus typically first appears in individuals who are in their late teens or early twenties, and may progress for 10-20 years and then slow or stabilize. Each eye may be affected differently. In the early stages of keratoconus, people might experience:

  • Slight blurring of vision
  • Distortion of vision
  • Increased sensitivity to light

The cornea is responsible for focusing most of the light that comes into the eye. Therefore, abnormalities of the cornea, such as keratoconus, can have a major impact on how an individual sees the world, making simple tasks such as driving a car or reading a book very difficult.

 

Keratoconus:

  • Can result in significant vision loss
  • May lead to corneal transplant in severe cases
  • Affects both males and females
  • Affects all ethnicities
  • 10% of people with KC have affected relatives
  • People with Down syndrome are 20 times more likely to be affected

You can find more information from the National Keratoconus Foundation at www.NKCF.org.

What Is iLink™ Corneal Cross-Linking?

iLink™ corneal cross-linking is a minimally invasive outpatient procedure that combines the use of ultraviolet light and specially formulated eye drops to stiffen and strengthen corneas that have been weakened by disease or refractive surgery. Cross-linking is considered the standard of care around the world for progressive keratoconus and corneal ectasia following refractive surgery.2

Is iLink™ Covered by Insurance?

The medical necessity of iLink™ has become widely recognized. As a result, commercial insurance coverage for the procedure is now over 95% in the United States.